Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis - Wikidata - wikimedia - TriplyDB

Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis

Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis

http://www.wikidata.org/entity/Q35222076

about

Clinical immunologic approaches for the treatment of Alzheimer's disease Alzheimer's disease as homeostatic responses to age-related myelin breakdown Active and passive immunotherapy for neurodegenerative disorders Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy Chemical and neuropathological analyses of an Alzheimer's disease patient treated with solanezumab Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors White matter changes in dementia: role of impaired drainage of interstitial fluid.Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates.DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patients Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology Targeting Abeta and tau in Alzheimer's disease, an early interim report Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease.Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy The biochemical aftermath of anti-amyloid immunotherapy.Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy.A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies.The inflammatory response in Alzheimer's disease.Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice Investigating interventions in Alzheimer's disease with computer simulation models Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease.Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials.Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts.Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease.Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease.An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect.Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.

P2860

Q22241380-7300AF0C-3388-4204-AEFF-991FB4BECBC6 Q22251261-62484853-0566-487C-8F3D-1F1877A3DAC6 Q24657879-E1440F12-99A1-49F7-9B23-0A9E57C6351D Q28066906-E9C7BA75-9D28-4697-8C68-F8A8999EE7DB Q28488690-18008443-0AE0-473A-8BE0-7C09EA20614E Q28828354-3975500B-ADAC-4F52-B06A-099F25022527 Q30486176-8C775C72-633B-4F3E-91DE-AEB807B71929 Q30497637-C0E5DB41-562C-4980-AD0E-2A48CC395F65 Q30880445-99A34DC3-7F62-4654-8A36-069A70B28860 Q33332164-1E40ACBA-B47C-4354-913B-081D3683C373 Q33560798-1C69A201-E03D-4D2C-81D3-F9CD6BBBD3E4 Q33647708-62EDBD8A-00EC-4EE0-B491-B94F7F328042 Q33691958-6F59465B-CF84-432A-8BF6-4A1BC20735EC Q33801986-FD34FEAA-66AE-44DE-930F-BEAF296A079F Q33808402-559810CF-7B62-4F84-A085-B8FA156F9CA7 Q33829008-C17D72E3-BA83-4AAC-B333-577FDA2BB181 Q34080692-54A521FA-3404-4D60-86C1-4F7D77C22673 Q34219814-F476E4FC-A8F2-48D0-8C41-85DD77C350CA Q34221510-40540EEB-E4D9-4945-A7C7-45556C9F76E7 Q34286389-0F62FE7D-F6C3-4207-9354-03746AB06421 Q34298878-D952EA79-00BB-4A28-833A-B885D11E6E6C Q34368970-6D5B43D0-CE57-47A3-92A0-8FA24F03F26A Q34376103-3DBCBC6F-B54E-40B3-8746-508389F5EB7A Q34518856-E176EC4B-D65E-44DD-AF33-53A386A02AAD Q34803247-1858BCBB-1356-478C-8206-2156628C09CF Q34948575-5BF84346-7C3C-467B-9D5F-ACBE99FC6B92 Q35009820-D8ED2136-357F-401E-8F01-7B70BE6DA097 Q35156471-2FB75EC4-B96D-49E6-9E67-54CA44F273C9 Q35183183-2A42E51F-5E1E-40F5-82CF-C31C68F37E7F Q35549137-0C88A27F-2FA6-42C6-96E9-87FCF7D95495 Q35695716-E639D907-2685-453D-B940-7C15A41C4F5D Q35767208-4805BF14-4615-434A-82B5-1F92E7746F36 Q35818921-6046E57B-FE69-45A5-B07C-47E460836966 Q35862439-EE7DAAEA-E156-4020-91F8-6953E7291B15 Q36002121-0502C2A3-ED58-4CEE-9112-B0416BB0E123 Q36121377-28C11E4D-9E00-49A7-9E80-7F20EC8C83FC Q36240389-D3A8B634-CD6F-4C12-877D-3B033EECD2CE Q36526176-277A3701-B220-4D98-A95B-0355BF329EA9 Q36576263-BC71EC42-16F3-4EB0-A50A-92441DD0FF29 Q36631376-6522A536-0AF8-430A-9E5D-3EA9E0C03358

P2860

Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis

http://www.wikidata.org/entity/Q35222076

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Amyloid-beta peptide remnants ...... tients: a biochemical analysis

@ast

Amyloid-beta peptide remnants ...... tients: a biochemical analysis

@en

type

label

Amyloid-beta peptide remnants ...... tients: a biochemical analysis

@ast

Amyloid-beta peptide remnants ...... tients: a biochemical analysis

@en

prefLabel

Amyloid-beta peptide remnants ...... tients: a biochemical analysis

@ast

Amyloid-beta peptide remnants ...... tients: a biochemical analysis

@en

P1433

Q35222076-EF4135DA-07ED-4871-9657-AF9699514512

P1476

Q35222076-CDDF3828-968F-474A-BB2D-C3628F43A034

P2093

Q35222076-0C7AAA57-A9D3-4A5A-AA30-34289DB11747

Q35222076-0EC1831A-8D38-45E1-994A-19BC6D2E8F20

Q35222076-115A9172-A3F3-437D-9738-EC2ABA20CD42

Q35222076-3861CBE2-CFDC-4B2E-842C-727C550B9286

Q35222076-3E1404BE-F751-4B2D-A0E9-BBFF886426A6

Q35222076-42294CF1-861E-4A36-8613-DEB67EC85B7B

Q35222076-52A9892C-CE0E-4DF3-BD18-54C4B85D318F

Q35222076-784F07B9-E6E0-4811-8FD0-FE5C750B94A7

Q35222076-89CCBFB4-9D87-4827-ACE3-D8B4BF39A413

Q35222076-8A3264E1-1C11-4923-9DB2-8E5E53DDE81F

P2860

Q35222076-05FC2060-E217-48A4-84D0-86578DA6B94A

Q35222076-0CA37260-D119-4293-95EC-F16A4CE33986

Q35222076-1203F949-E6FA-4DC3-B4D0-2961873D759A

Q35222076-12163231-7189-4B24-B3CA-8981BD7036EA

Q35222076-174EFA64-E2E6-429E-BC8E-838F218D634C

Q35222076-205CA61D-0454-432E-9238-141FCEFC0712

Q35222076-24ABC500-C3C0-45CF-8668-29F3963E2269

Q35222076-25ED3A86-1270-4C18-8336-F512E3E82283

Q35222076-27237F1C-123E-4FCC-B237-4145304D4AFF

Q35222076-2EF3790C-AB57-4889-9FFC-CD3EC7DD5C2F

P304

Q35222076-8EFA10CF-4BDB-4823-910E-B58BE57A0E22

P31

Q35222076-537C55A9-69CD-486B-9500-17CBC0E01A6D

P356

Q35222076-DF013A84-A6F1-4CC8-BA11-C6E2E723687A

P407

Q35222076-CC05C2F6-1581-4642-A476-42263D36174B

P433

Q35222076-47B4105B-AD1B-451F-ADC4-DED8247BFDD4

P478

Q35222076-786DB75C-8D42-49DC-B39D-7E352639E81C

P50

Q35222076-2DBF42BF-0E32-43B4-A55A-03CFB69266CE

Q35222076-707C3967-A9FD-4F0E-A582-CB88806DCC46

P577

Q35222076-A1E7B406-CAD0-4842-AB46-6DD027F8EFCF

P5875

Q35222076-7902FF05-4674-4DD5-9B4B-C988BD1F4632

P698

Q35222076-3D429804-B87F-4622-AD71-1F4D42BD2034

P921

Q35222076-408EBB88-5D1B-4DFE-9125-8171547320BF

Q35222076-4F28803E-9545-481D-9C7E-43030245C8B7

P932

Q35222076-D0BCF00A-112F-43C7-9C2A-A5E4A988DCB5

P356

AJPATH.2006.060269

P1433

The American Journal of Pathology

P1476

Amyloid-beta peptide remnants ...... tients: a biochemical analysis

@en

P2093

Alex E Roher

http://www.w3.org/2001/XMLSchema#string

Amanda J Newel

http://www.w3.org/2001/XMLSchema#string

Chera L Esh

http://www.w3.org/2001/XMLSchema#string

Daniel Brune

http://www.w3.org/2001/XMLSchema#string

Dean C Luehrs

http://www.w3.org/2001/XMLSchema#string

Eduardo M Castaño

http://www.w3.org/2001/XMLSchema#string

Gregory D Van Vickle

http://www.w3.org/2001/XMLSchema#string

Isidro Ferrer

http://www.w3.org/2001/XMLSchema#string

John Lopez

http://www.w3.org/2001/XMLSchema#string

R Lyle Patton

http://www.w3.org/2001/XMLSchema#string

P2860

Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease

beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease

P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain

Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease.

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

Isolation and chemical characterization of Alzheimer's disease paired helical filament cytoskeletons: differentiation from amyloid plaque core protein

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

P304

1048-1063

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/AJPATH.2006.060269

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

169

http://www.w3.org/2001/XMLSchema#string

P50

Eliezer Masliah

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6852856

http://www.w3.org/2001/XMLSchema#string

P698

16936277

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

1698828

http://www.w3.org/2001/XMLSchema#string